Product Description
Teriflunomide is in a class of medications called immunomodulatory agents. It is thought to work by decreasing inflammation and decreasing the action of immune cells that may cause nerve damage. (Sourced from: https://medlineplus.gov/druginfo/meds/a613010.html)
Mechanisms of Action: DHODH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting
Known Adverse Events: Headache | Alopecia | Diarrhea
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Latvia, Lithuania, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Multiple Sclerosis
Phase 1: Multiple Sclerosis, Relapsing-Remitting
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-001292-21 | P3 |
Active, not recruiting |
Multiple Sclerosis |
2025-07-04 |
|
| GEMINI 2 | P3 |
Completed |
Multiple Sclerosis |
2024-07-16 |
|
| GEMINI 1 | P3 |
Completed |
Multiple Sclerosis |
2024-07-15 |
|
| CTR20222095 | P1 |
Recruiting |
Multiple Sclerosis, Relapsing-Remitting |
None |